Try our Advanced Search for more refined results

KING DRUG COMPANY OF FLORENCE, INC. et al v. ABBOTT LABORATORIES et al

  1. September 19, 2024

    AndroGel Antitrust Case On Hold Amid Settlement Talk

    A Pennsylvania federal judge has agreed to pause a class action against Abbott and other drugmakers over allegedly sham patent cases, saying a settlement between the two sides may be in the works.

  2. August 23, 2024

    Drugmakers' 'Subjective Beliefs' Obscured In Antitrust Case

    A Pennsylvania federal judge has denied a request from direct purchasers of pharmaceuticals to compel the leaders of Abbott Laboratories and other companies to express "subjective beliefs" about sham patent litigation they allegedly engaged in, dismissing the purchasers' fears that the companies would change their position on certain issues at the last minute during trial.

  3. November 29, 2023

    AbbVie Tells 3rd Circ. 'Sham' Case Ruling 'Explodes' Privilege

    Judges on a Third Circuit panel were skeptical Wednesday of arguments from AbbVie Inc. that a lower court's ruling on discovery of attorney communications in a "sham" patent case would open the floodgates to privilege challenges any time a drug company files a suit that slows down a competitor.

  4. March 27, 2023

    Court Eyes Attorney Actions In 'Sham' Androgel Patent Suit

    AbbVie Inc. and Besins Healthcare Inc. will have to turn over 100 documents previously deemed protected by attorney-client privilege, so a Pennsylvania federal judge can determine whether there's evidence that patent litigation they filed more than a decade ago was a sham.

  5. January 20, 2023

    AndroGel Patent Suit Ruled Baseless For Antitrust Claims

    A Pennsylvania federal court ruled that an infringement case filed in 2011 by AbbVie and Besins over AndroGel was objectively baseless, siding with drug wholesalers on a key allegation in their suit accusing the companies of delaying generic versions of the testosterone drug.

  6. March 24, 2022

    AndroGel Buyers Can't Use FTC Case Against AbbVie, Besins

    Drug wholesalers suing AbbVie and Besins for delaying generic Androgel from hitting the market can't stop the pharmaceutical companies from relitigating issues that the buyers said were already decided in a Federal Trade Commission action, a Pennsylvania federal judge has ruled.

  7. April 02, 2021

    AndroGel Makers, Buyers Clash Over FTC Getting Discovery

    Pharmaceutical companies scolded plaintiffs waging an antitrust fight over testosterone treatment AndroGel for asking a Pennsylvania federal court to let them share sensitive records obtained through discovery with the Federal Trade Commission.

  8. January 07, 2020

    AndroGel Antitrust Case Won't Get Moved To Georgia

    A Pennsylvania federal judge has turned down an effort by the makers of AndroGel to move an antitrust suit over generic competition out of the Keystone State and combine it with similar litigation in Georgia, saying the suits' claims are insufficiently linked.

  9. November 26, 2019

    AbbVie Says AndroGel Suit Should Be Moved To Georgia

    AndroGel maker AbbVie has told a Philadelphia federal judge that an antitrust suit against the company in Pennsylvania should be consolidated with a similar suit in Georgia even though only one plaintiff remains in the Georgia case.

  10. November 22, 2019

    New Deal Anchors AndroGel Antitrust Suit To Pa., Buyers Say

    In a move that could impact a bid to transfer an antitrust suit against AndroGel maker AbbVie Inc. and its affiliates from Pennsylvania to multidistrict litigation in Georgia, a group of direct purchasers and retailers said on Thursday that they have agreed to settle claims in the Keystone State.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!